Highly variable NTID [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2015-09-23 10:23 (3464 d 15:24 ago) – Posting: # 15454
Views: 17,310

Dear Helmut,

❝ ❝ I had interpreted the sentence "Dabigatran demonstrated a steep exposure response relationship for both efficacy and safety." as some sort of NTID.


❝ Me too. Seems that the innovator (Boehringer Ingelheim) assessed the variabilities in its studies.

❝ This is the first example I’m aware of were the observation “HVDs/HVDPs are safe drugs since they have a flat dose/response-curve” seemingly does not hold.


Oh I see. That's the reason for the sentence "Therefore applicants should not use the reference-scaled average bioequivalence (BE) approach to widen the BE limits for dabigatran BE evaluation" in the dabigatran guidance.

Seems it's time for a new term: HVNTID :cool:

❝ A dirty story? Wikipedia ...


A really dirty story :vomit:. So much to "To cheat is Indian" (My exculpation to the Indian members of this forum).

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,669 registered users;
21 visitors (0 registered, 21 guests [including 9 identified bots]).
Forum time: 00:47 CET (Europe/Vienna)

I have not failed 700 times. I have not failed once.
I have succeeded in proving
that those 700 ways will not work.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5